Clone PPG5/10 recognizes Estrogen Receptor Beta (ER?) 1 and is useful in determining the expression of ER?1 in cancer cells, mainly via immunohistochemistry.
| Institute |
|---|
| BioServ UK Ltd |
| Cat. #: | 153631 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Cancer types: | Ovarian cancer, Breast cancer |
| Research Fields: | Cancer;Immunology;Neurobiology |
| Application: | IHC ; IF ; WB |
| Target: | Estrogen Receptor ?1 |
| Reactivity: | Human ; Pig ; Primate ; Rat ; Sheep ; Rhesus macaque ; Cynomolgus monkey ; Turtle ; Goose |
| Clone: | PPG5/10 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Estrogen receptor beta, ER-beta, Nuclear receptor subfamily 3 group A member 2 |
|---|---|
| Product description: | Estrogen receptors are commonly over-expressed in cancers. Clone PPG5/10 recognizes Estrogen Receptor Beta (ERÄÂ?) 1 and is useful in determining the expression of ERÄÂ?1 in cancer cells, mainly via immunohistochemistry. |
| Conjugation: | Unconjugated |
| Isotype: | IgG2a |
| Molecular weight: | 59 kDa |
| Immunogen: | Synthetic peptide CEDSKSKEGSQNPQSQ derived from the C terminus of human ER?1 |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | Estrogen receptors are commonly over-expressed in cancers. Clone PPG5/10 recognizes Estrogen Receptor Beta (ER?) 1 and is useful in determining the expression of ER?1 in cancer cells, mainly via immunohistochemistry. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Zannoni et al. 2016. Histopathology. 68(4):541-8. PMID: 26132417. Sexual dimorphism in medulloblastoma features. Gender effect in experimental models of human medulloblastoma: does the estrogen receptor ? signaling play a role? Ciucci et al. 2014. PLoS One. 9(7):e101623. PMID: 25000562. Asgari et al. 2011. Diagn Pathol. 6:61. PMID: 21733187. Estrogen receptor beta expression in prostate adenocarcinoma. Collins et al. 2009. BMC Cancer. 9:330. PMID: 19758455. Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha. Schiessl et al. 2005. J Histochem Cytochem. 53(12):1441-9. PMID: 15983116. Wong et al. 2005. J Pathol. 207(1):53-60. PMID: 15954165. ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. Expression of endothelial NO synthase, inducible NO synthase, and estrogen receptors alpha and beta in placental tissue of normal, preeclamptic, and intrauterine growth-restricted pregnancies. Sierens et al. 2004. J Mol Endocrinol. 32(3):703-18. PMID: 15171710. Cloning of oestrogen receptor beta from Old and New World primates: identification of splice variants and Fn analysis. Torlakovic et al. 2002. Hum Pathol. 33(6):646-51. PMID: 12152165. Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score. |
|---|
Clone PPG5/10 used to detect expression of ER?1 in cancer tissue by IHC-P. Immunoexpression of ERs in endometrial cancers. Antibody dilution used 1







| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.